Jennifer Durham

Medicine & Life Sciences

1. Adenocarcinoma 100%
2. Turcot syndrome 98%
3. Immunotherapy 88%
4. T-Lymphocytes 77%
5. Nivolumab 77%
6. Cancer Vaccines 76%
7. Survival 72%
8. Neoplasms 67%
9. Cyclophosphamide 65%
10. Pancreatic Neoplasms 64%
11. GVAX vaccine 62%
12. DNA Mismatch Repair 61%
13. Ipilimumab 56%
14. Colorectal Neoplasms 56%
15. Immunity 52%
16. mesothelin 49%
17. Granulocyte-Macrophage Colony-Stimulating Factor 49%
18. Vaccines 44%
19. Neoadjuvant Therapy 39%
20. Vaccination 35%
21. Tumor Microenvironment 35%
22. Feasibility Studies 32%
23. Therapeutics 32%
24. Progression-Free Survival 30%
25. cabozantinib 30%
26. pembrolizumab 28%
27. Mutation 26%
28. Oncogenes 26%
29. Programmed Cell Death 1 Receptor 26%
30. acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 25%
31. Pancreas 25%
32. Confidence Intervals 24%
33. Microsatellite Instability 24%
34. romidepsin 22%
35. Hepatocellular Carcinoma 22%
36. Safety 22%
37. Tumor Burden 21%
38. Microsatellite Repeats 20%
39. Response Evaluation Criteria in Solid Tumors 19%
40. Genes 19%
41. Antibodies 18%
42. Listeria 18%
43. Azacitidine 18%
44. Genetic Selection 18%
45. Listeria monocytogenes 17%
46. Colon 17%
47. Methyltransferases 17%
48. Induction Chemotherapy 16%
49. Thyroglobulin 16%
50. Trastuzumab 16%